{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(40)"],"submitter":["Song Y"],"pubmed_abstract":["Selective elimination of senescent cells (senolysis) has become a promising therapeutic strategy for the management of chronic renal failure (CRF), but the senolytic molecular pathways towards CRF therapy are limited. Here, we present for the first time a senescence-associated β-galactosidase (SA-β-gal) activatable theragnostic prodrug strategy to pertinently and effectively treat CRF in mice with the aid of fluorescence-guided senolysis. The signs of premature senescence, including the overexpression of β-gal, have been found in kidneys of mice with CRF, making this enzyme particularly suitable as a trigger of prodrugs for CRF therapy. With this unique design, our pioneering prodrug TSPD achieved the activation of a fluorophore for tracking and the specific release of the parent drug, gem"],"journal":["Chemical science"],"pagination":["11738-11745"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9580481"],"repository":["biostudies-literature"],"pubmed_title":["A senolysis-based theragnostic prodrug strategy towards chronic renal failure."],"pmcid":["PMC9580481"],"pubmed_authors":["Li X","Li J","Qiao S","Guo Y","Sun T","Shi D","Chen X","Song Y","Liu W"],"additional_accession":[]},"is_claimable":false,"name":"A senolysis-based theragnostic prodrug strategy towards chronic renal failure.","description":"Selective elimination of senescent cells (senolysis) has become a promising therapeutic strategy for the management of chronic renal failure (CRF), but the senolytic molecular pathways towards CRF therapy are limited. Here, we present for the first time a senescence-associated β-galactosidase (SA-β-gal) activatable theragnostic prodrug strategy to pertinently and effectively treat CRF in mice with the aid of fluorescence-guided senolysis. The signs of premature senescence, including the overexpression of β-gal, have been found in kidneys of mice with CRF, making this enzyme particularly suitable as a trigger of prodrugs for CRF therapy. With this unique design, our pioneering prodrug TSPD achieved the activation of a fluorophore for tracking and the specific release of the parent drug, gem","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-05T13:27:42.683Z","creation":"2025-04-05T13:27:42.683Z"},"accession":"S-EPMC9580481","cross_references":{"pubmed":["36320912"],"doi":["10.1039/d2sc03525a"]}}